Amyloid-beta (1-40) CSF ELISA

Do you have a question about this product? We look forward to your e-mail!

Open e-mail form

Details for:  Amyloid-beta (1-40) CSF ELISA
In 2010, the number of dementia patients worldwide was estimated at 36 million. Assuming an ongoing lack of sufficient preventive and curative treatments, this is expected to double every 20 years. Alzheimer’s Disease accounts for roughly 60-70% of all dementia cases. Both prevalence and incidence increase with age. Prevalence is around 1% in those aged 65-69, and more than 30% in those aged 90 or older.

The development of the Disease is characterized by three stages, as defined by the US National Institute on Aging workgroups. A preclinical stage of Alzheimer’s Disease, the mild cognitive impairment (MCI) stage due to AD, and the dementia stage due to AD [9-11]. Amyloidosis occurs as early as the preclinical stage. The first cognitive deficits can manifest themselves in MCI stage, while in the dementia stage patients are unable to do any work or daily chores.
For concrete data please consult the Instruction for Use in the download box on the right side.

Catalog No. RE59651

Amyloid-beta (1-40) CSF ELISA
List Price $587
Kit size 12 x 8
Method ELISA
Incubation time 1 x 2h, 1 x 1h, 1 x 30 min.
Standard range 188 - 1880 pg/mL
Specimen / Volumes 5 µL CSF
Substrate / isotope TMB 450nm
Regulatory Status: For research use only


Aus technischen Gründen können seit dem 23 Okt. 2020 nicht alle Dokumente für den Download zur Verfügung gestellt werden. Wir senden Ihnen die gewünschten Unterlagen gerne per Mail zu.

Anfrage an den Technischen Support senden >

For technical reasons, not all documents can be made available for download since 23 Oct. 2020. We will be happy to send you the requested documents by e-mail.

Send request to the technical support >